Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07402343 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tarlatamab for SCLC Brain Metastases

Study acronym: T-BRAIN
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Start date: May 2026 to Aug 2026
    • Site details revised at 4 of 4 sites
    v4
  2. Start date: Feb 2026 to May 2026
    • Enrollment target: 34 to 35
    v3
  3. Secondary endpoints: 6 to 8v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Trial Details
NCT Number NCT07402343
Lead Sponsor Maastricht University Medical Center
Collaborators: The Netherlands Cancer Institute, Erasmus Medical Center, University Medical Center Groningen
Conditions
(from sponsor)		 Small Cell Lung Cancer, Brain Metastases, Adult
Related terms Brain Neoplasms, Small Cell Lung Carcinoma
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov